Body Protection Compound fragment
Experimental peptide
BPC-157 is a synthetic peptide studied mainly in animal injury models. A rat Achilles tendon experiment suggests a research question, but it does not establish faster tendon, ligament or muscle recovery in people. FDA staff reviewed a different proposed use, ulcerative colitis, in July 2026 and described major evidence and safety gaps. The review did not establish an injury-recovery benefit.
Limited or indirect human evidence; confidence varies by outcome
Regulatory Status: No FDA-approved BPC-157 drug. FDA staff reviewed BPC-157 for compounding in July 2026; that review is not an approval or a final rule.
Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.
Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.
BPC-157 accelerates recovery from human tendon, ligament or muscle injuries.
Why this rating
The cited Achilles-tendon experiment was in rats. A clinical recovery benefit cannot be inferred from it.
Supporting studies
A tendon-repair signal in rats, not a human healing outcome.
BPC-157 reduces chronic knee pain.
Why this rating
A retrospective series cannot separate BPC-157 from placebo effects, co-interventions or natural change.
GRADE downgrade factors applied
Supporting studies
Uncontrolled report of knee-pain outcomes; no randomized comparator.
BPC-157 heals human gastrointestinal disease.
Why this rating
FDA’s 2026 briefing reviewed ulcerative colitis but found insufficient evidence for clinical use and unresolved safety questions.
Supporting studies
Review of the nominated ulcerative-colitis use identified major evidence gaps.
There is no FDA-approved BPC-157 recovery indication or established human dosing protocol. Animal doses and online injection schedules should not be converted into personal treatment instructions.
Need to mix this from a vial?
Use our reconstitution calculator to get the exact insulin syringe units to draw.
PubMed, 2008
A rat injury experiment; it does not establish human recovery benefit.
View StudyU.S. Food and Drug Administration, 2026
FDA staff reviewed nominated BPC-157 for ulcerative colitis, described limited human information and did not review tendonitis efficacy because the nomination lacked sufficient information.
View StudyHSS Journal, 2025
The review identified mostly preclinical studies and advised against clinical musculoskeletal use pending well-designed human trials.
View StudyAnimal findings do not establish a human injury treatment. Compare the exact molecules and evidence limits.
For medical decisions, discuss established options with a licensed clinician.Human outcome evidence here is limited.
No FDA-approved BPC-157 drug exists. FDA staff reviewed a nomination in 2026; a review or advisory discussion is not an approval.
The cited tendon experiment was in rats. A controlled human trial showing faster tendon healing or return to function is needed.
No. An uncontrolled retrospective report cannot show whether BPC-157 caused the change.
No approved indication or validated human recovery protocol establishes a dose, route or injection site.
No controlled human trial establishes the efficacy or safety of that combination for injury recovery.
Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.
Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated October 2026.